Pneumococcal Bacteremia and Cryptococcal Meningitis Dual Infection in a Patient With Multiple Myeloma

Abdul Raheem 1, Balram Rathish 2, Deepak Charles 3, Arun Wilson 2, Anup Warrier 2

1. Internal Medicine, Aster Medcity, Kochi, IND 2. Infectious Diseases, Aster Medcity, Kochi, IND 3. Hematology, Aster Medcity, Kochi, IND

Corresponding author: Balram Rathish, balramrnair@gmail.com

Abstract

Infections remain one of the major complications in patients with multiple myeloma, having a significant impact on morbidity and mortality. The increased risk of infection in these patients are a result of various factors contributing to the impairment of immune system caused by the disease and the chemotherapy regimens given during the treatment phases. Here we report a rare case of pneumococcal bacteremia and cryptococcal meningitis dual infection in a patient with underlying multiple myeloma who had a favourable clinical outcome. This case also serves to highlight the importance of adult vaccinations especially in patients with underlying comorbidities.

Categories: Internal Medicine, Infectious Disease, Hematology
Keywords: pneumococcal bacteremia, cryptococcal meningitis, multiple myeloma, streptococcus pneumoniae, cryptococcus neoformans

Introduction

Multiple myeloma (MM) forms about 10% of all hematological malignancies. The uncontrollable proliferation of plasma cells affects the normal functioning of the immune system, predisposing to infections in these patients [1]. Over the years, the survival rates in MM have improved significantly by virtue of newer treatments regimens [2-4]. Hence, the management of infections, which is one of the most common complications of MM, holds great importance [5]. A report of more than 3,000 MM patients showed that early deaths, which happened within six months of a diagnosis of MM, were directly due to infections (45%) [6]. Other reports have suggested that some of the newer chemotherapy regimens have made the patients more prone to infection and that this can lead to an increased mortality [7,8].

Bacterial as well as fungal respiratory tract infections (RTIs) are very common in patients with hematological malignancies and this may even progress to sepsis [9,10]. Opportunistic fungal infections, including cryptococcosis, generally affect immunocompromised patients due to the suppression of cell-mediated immunity [11]. Here we report a rare case of pneumococcal bacteremia and cryptococcal meningitis dual infection in a patient with underlying MM, which proved to be a diagnostic as well as therapeutic challenge.

Case Presentation

A 60-year-old man with underlying MM and liver cirrhosis was admitted with fever and a non-productive cough for two days. He had undergone four cycles of chemotherapy with cyclophosphamide, bortezomib, and dexamethasone in the past, which were later changed to pomalidomide, dexamethasone, and zoledronate. His last chemotherapy cycle was two weeks prior to the present admission. Prior to the initiation of chemotherapy, he was advised pneumococcal, meningococcal, and other adult vaccinations but he had refused.

Clinical examination showed pallor and icterus. He had tachycardia, tachypnea, and an elevated temperature of 100 F. Examination of the chest revealed diffuse crepitations on bilateral lung fields. An abdominal exam revealed hepatomegaly with ascites. Neurological examination was unremarkable with no signs of meningeal irritation.

A chest X-ray showed the right middle lobe and left lingular consolidation (Figure 1). His C-reactive protein was 172 (<10 mg/dL), serum sodium was 125 (134-145 mmol/L), and albumin was 1.9 (3.5-5.5 g/dL). A computed tomography (CT) chest showed consolidation with collapse involving the left lingular segment, along with peri-brochial consolidation in the anterior segment of the right upper lobe suggestive of an infective etiology (Figure 2). A diagnosis of community-acquired pneumonia was made and he was started on broad-spectrum antibiotics (ceftriaxone) as per the local antibiogram after obtaining blood, sputum, and urine for microbiological culturing.
FIGURE 1: Chest X-ray showing right middle lobe (red arrow) and left lingular consolidation (blue arrow).
FIGURE 2: CT chest showing a consolidation involving the left lingular segment (blue arrow) along with peri-bronchial consolidation in the anterior segment of the right upper lobe (red arrow).

CT - computed tomography

On day 2, his blood culture grew gram-positive cocci, which were identified to be penicillin-sensitive *Streptococcus pneumoniae*. His antibiotic was continued and he remained afebrile. However, on day 4, he developed a persistent fever. The ceftriaxone was changed to piperillin-tazobactum. Repeat blood cultures on day 7 were negative with no persistent bacteremia or secondary infection, and CRP showed a reducing trend. But he continued to have febrile episodes despite completing 10 days of antibiotics. In view of persistent fever in an immunosuppressed patient, possibilities of local complications like empyema and lung abscess were considered and levofloxacin was added. A repeat CT chest along with CT abdomen was performed, which did not show any local collections in the lung or any visceral abscess. Ascitic fluid analysis revealed no features of spontaneous bacterial peritonitis. An echocardiogram revealed no evidence of Infective endocarditis.

On day 12, he developed altered sensorium with slurring of speech. MRI brain revealed ischemic infarcts in the internal capsules (Figure 3). Since fever was persisting, the possibility of a meningeal infection was suspected even though there were no clinical signs of meningism. Since piperillin-tazobactum and levofloxacin would not penetrate the blood-brain barrier adequately, the antibiotic was changed to ceftriaxone at a meningitic dose. Serum galactomannan was elevated at two (<0.5), and hence voriconazole was added. Cerebrospinal fluid (CSF) study showed a total count of 45 cells/µL (0-5 cells/µL), which were all lymphocytes, sugar of 110 mg/dL (paired serum sugar of 82 mg/dL), and protein of 135 (15-60 mg/dL). Tubercular and fungal meningitis were considered the differential diagnosis. Acid-fast staining and GeneXpert® (Cepheid, Sunnyvale, California, United States) were negative. CSF India ink staining revealed capsulated yeasts suggestive of *Cryptococcus neoformans*, which was confirmed using a lateral flow assay for cryptococcal antigen. He was treated with flucytosine and amphotericin-B for two weeks following which he improved clinically. He remained afebrile, conscious, and alert throughout the rest of the hospital stay and was discharged at the end of two weeks with oral fluconazole to be continued for 10 weeks. A repeat CSF study done on follow up was negative for *Cryptococcus*.
**FIGURE 3:** Diffusion-weighted MR showing ischemic infarcts in bilateral internal capsules.

**Discussion**

MM patients tend to have a low immune response to vaccines, which predisposed them to contract the infection despite vaccinations [12,13]. This patient was advised to take pneumococcal vaccination prior to the initiation of chemotherapy, but he had refused which directly contributed to pneumococcal pneumonia and bacteremia. Assessment for the risk of infection in MM patients should be done before and during the treatment of MM. Detailed past medical history, risk factors, screening for any infections, and the vaccinations administrated should be taken to make relevant prophylactic measures for each patient. It is recommended to vaccinate against *S. pneumoniae* at the time of diagnosis of MM in the patient and vaccination against influenza for family members yearly to prevent infections to some extent. It is better to recommend antibacterial, antifungal, and antiviral prophylaxis considering the phase of the disease and treatment type for each patient [14].

Cryptococcal infection in the central nervous system may manifest as meningitis and as meningoencephalitis with a variable clinical presentation. *Cryptococcus* causes opportunistic infection resulting in high morbidity and mortality. Some reports have shown that the acute mortality due to cryptococcal meningitis remains high (30% to 50%), even with adequate antifungal therapy. Other studies have shown that cryptococcal meningitis can cause considerable morbidity and survivors may have a residual visual impairment, hearing loss, or neurocognitive impairment that may be irreversible [15,16]. Our patient however had a very good clinical outcome with no residual neurological impairment. He was treated with amphotericin B and flucytosine. Combination therapy using amphotericin B and flucytosine had shown increased rates of fungal clearance when compared with four-week amphotericin monotherapy. The currently accepted treatment regimen for cryptococcal meningitis involves induction with amphotericin B (0.7-1.0 mg/kg/day) along with flucytosine (100 mg/kg/day) for two weeks. Followed by consolidation and maintenance, fluconazole at 400 mg/day for 8 to 12 weeks and at 200 mg/day for 6 to 12 months, respectively [17,18].

The patient was having hyponatremia on admission and the initially altered sensorium was thought to be due to that, but could very well have been due to the acute cerebral infarcts. The sensorium remained the same even after the correction of serum sodium and the fever persisted even after pneumonia subsided. This led to the search for another underlying infection and identification of cryptococcal meningitis. Although multiple infections may be encountered in immunosuppressed patients, this type of dual infection involving...
an unusual pathogen causing a bloodstream infection with concurrent fungal meningitis is very rare and the
timely diagnosis together with rapid institution of appropriate therapy resulted in a favourable outcome in
our patient.

Conclusions
Dual infections are rarely encountered especially in the setting of immunosuppression. This case serves to
highlight that infections in immunocompromised patients should be high on the differential in patients
presenting with symptoms in order to prevent morbidity and mortality. If the symptoms do not subside even
with appropriate treatment of the infection, co-existing infections should be high on the list of differentials
in such patients.

Timely diagnosis and rapid institution of appropriate therapy are paramount in improving clinical outcomes
in such patients. Adult vaccination also forms an important step in the treatment of an
immunocompromised patient in order to prevent vaccine-preventable diseases. Patients should be
encouraged to get vaccinated at the earliest. Patients should also be educated regarding the lifestyle
modifications necessary to minimize the risk of acquiring common infections.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In
compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services
info: All authors have declared that no financial support was received from any organization for the
submitted work. Financial relationships: All authors have declared that they have no financial
relationships at present or within the previous three years with any organizations that might have an
interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.

References
1. De Smedt E, Lui H, Maes K, De Veirman K, Menu E, Vanderkerken K, De Bruyne E: The epigenome in
multiple myeloma: impact on tumor cell plasticity and drug response. Front Oncol. 2018, 8:566.
10.3389/onc.2018.00566
2. Kumar SK, Dispenzieri A, Lacy MQ, et al.: Continued improvement in survival in multiple myeloma: changes
in early mortality and outcomes in older patients. Leukemia. 2014, 28:1122-8. 10.1038/leu.2013.513
3. Kristinsson SY, Anderson WF, Landgren O: Improved long-term survival in multiple myeloma up to the age
of 80 years. Leukemia. 2014, 28:1546-8. 10.1038/leu.2014.25
4. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M: Patterns of survival in multiple
myeloma: a population-based study of patients diagnosed in Sweden from 1975 to 2005. J Clin Oncol. 2007,
25:1993-9. 10.1200/JCO.2006.09.0100
5. Palumbo A, Mina R: Management of older adults with multiple myeloma. Blood Rev. 2015, 27:133-42.
10.1016/j.brrev.2015.04.001
6. Augustsson BM, Begum G, Dunn JA, et al.: Early mortality after diagnosis of multiple myeloma: analysis of
patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002—Medical
Research Council Adult Leukaemia Working Party. J Clin Oncol. 2005, 23:9219-26. 10.1200/JCO.2005.03.2086
7. Lavi N, Avivi I, Kra-Oz Z, Oren I, Hardak E: Community-acquired respiratory infections are common in
patients with non-Hodgkin lymphoma and multiple myeloma. Support Care Cancer. 2018, 26:2425-51.
10.1007/s00520-018-4079-5
8. Blimark C, Holmberg E, Mellqvist UH, et al.: Multiple myeloma and infections: a population-based study on
9253 multiple myeloma patients. Haematologica. 2015, 100:107-15. 10.3324/haematol.2014.107714
9. Maschmeyer G, Donnelly JP: How to manage lung infiltrates in adults suffering from haematological
malignancies outside allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016, 173:179-89.
10.1111/bjh.13934
10. Maschmeyer G, Carratalà J, Buchheidt D, et al.: Diagnosis and antimicrobial therapy of lung infiltrates in
febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases
Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol.
2015, 26:21-33. 10.1093/annonc/mdu192
11. Chayakulkeeree M, Perfect JR: Cryptococcosis. Infect Dis Clin North Am. 2006, 20:507-44, v-vi.
10.1016/j.idc.2006.07.001
12. Karlsson J, Andrénsson B, Kondori N, Erman E, Riedbeck K, Hogevik H, Wenneås C: Comparative study of
immune status to infectious agents in elderly patients with multiple myeloma, Waldenström’s
macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol.
2011, 18:969-77. 10.1128/CVI.00021-11
13. Hargreaves RM, Lea JR, Griffiths H, et al.: Immunological factors and risk of infection in plateau phase
myeloma. J Clin Pathol. 1995, 48:260-6. 10.1111/j.1365-2642.1995.tb05212.x
14. Alemu A, Richards JG, Oaks MK, Thompson MA: Vaccination in multiple myeloma: review of current
literature. Clin Lymphoma Myeloma Leuk. 2016, 16:495-502. 10.1016/j.clml.2016.06.006
15. Carlson RD, Rolfs MA, Birkenkamp KE, Nakasuji N, Rajasingham R, Meya DR, Boulware DR: Predictors of
neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study.
16. Day JN, Chau TTH, Wolbers M, et al.: Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013, 368:1291-302. 10.1056/NEJMoa1110404
17. Spadari CC, Wirth F, Lopes LB, Ishida K: New approaches for cryptococcosis treatment. Microorganisms. 2020, 8:613. 10.3390/microorganisms8040613
18. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, Bekker LG, Harrison T: Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007, 45:76-80. 10.1086/518607